Novo Nordisk's $1.1 Billion Sickle Cell Bet Cleared Its Phase 3 Test. The Hard Part Is Still Coming.
Novo Nordisk cleared a Phase 3 test for its sickle cell pill. Whether that matters commercially depends on what happens next in a market defined by $2 million gene therapies.
Novo Nordisk's etavopivat cleared the Phase 3 HIBISCUS trial, meeting the regulatory threshold for FDA filing, but the results fell below internal expectations despite Phase 2 showing promise with reduced vaso-occlusive crises and higher hemoglobin levels. The daily oral drug, acquired for $1.1 billion in 2022 targeting pyruvate kinase-R, now faces an uncertain commercial landscape dominated by one-time curative gene therapies priced at $2.2M-$3.1M per patient. The competitive dynamic creates a fundamental tension between etavopivat's recurring revenue model and gene therapies' curative positioning, with commercial success depending heavily on value-based pricing arguments rather than list price comparisons.
- •Etavopivat cleared Phase 3 HIBISCUS trial (~380 patients, 400mg daily vs placebo) meeting FDA filing requirements but missed Novo's internal expectations, with full dataset not yet publicly released.
- •Phase 2 data showed statistically meaningful trends toward fewer vaso-occlusive crises over 52 weeks and improved hemoglobin at 24 weeks, establishing proof of concept before the underwhelming Phase 3 readout.
- •Gene therapies Casgevy ($2.2M, Vertex/CRISPR) and Lyfgenia ($3.1M, bluebird bio) represent one-time curative options that fundamentally reshape the competitive calculus for chronic sickle cell therapies.
